- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06459154
The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson´s Disease.
The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson´s Disease. Randomized Control Trial
Parkinson's disease is a chronic, neurodegenerative disease of unknown cause, affecting elderly people over the age of 60. It is the second most common neurodegenerative disease, presenting psychomotor signs and symptoms that lead to impaired functionality and quality of life in affected individuals. Mixed reality involves the delivery of digital stimuli in real time and space through spatial mapping using glasses, safely providing multiple iterations to carry out daily activities.
Through this tool and in collaboration with technologically skilled mixed reality developers, the software for the rehabilitation program to be applied to Parkinson's disease patients was also developed.
The main objective of this clinical study is to examine the effect of a mixed reality program compared to a traditional physiotherapy program on quality of life and motivation for the participation of people with Parkinson's disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease is a chronic, neurodegenerative disease of unknown cause, affecting elderly people over the age of 60. It is the second most common neurodegenerative disease, presenting psychomotor signs and symptoms that lead to impaired functioning and quality of life in affected individuals. Mixed reality involves the delivery of digital stimuli in real time and space through spatial mapping using glasses, safely providing multiple iterations to carry out daily activities.
Through this tool and in collaboration with technologically skilled mixed reality developers, the software for the rehabilitation program to be applied to Parkinson's disease patients was also developed.
The main objective of this clinical study is to examine the effect of a mixed reality program compared to a traditional physiotherapy program on quality of life and motivation for the participation for people with Parkinson's disease.
The study will be divided into two phases, the first of which includes the translation and adaptation of the Intrinsic Motivation Inventory (IMI) questionnaire, which assesses motivation and is not available in Greek, and will be used in 300 healthy subjects to assess its psychometric characteristics.
The second phase of the clinical trial is a parallel, blinded, randomized study involving 45 patients.
This study will provide the opportunity to use innovative equipment that offers multiple stimuli increasing the interactivity of the participants to perform functional activities. This research is the first clinical study in Cyprus that will apply the reported rehabilitation tool aiming to improve and evaluate the quality of life, functionality and motivation of people with Parkinson's disease. Moreover, it enables the development of cognitive and motor rehabilitation by increasing the interaction of the individual with the environment and facilitating the completion of treatment goals.
The research using mixed reality and through a comparative process with traditional physiotherapy, aims to provide valid and reliable data to the general public and health scientists, facilitating the selection of appropriate means to provide a holistic treatment plan.
Translated with DeepL.com (free version)
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elena Papamichael, PhD Cand
- Phone Number: 00357 99886346
- Email: papamichael.e1@live.unic.ac.cy
Study Locations
-
-
Engomi
-
Nicosia, Engomi, Cyprus, 2408
- Recruiting
- University of Nicosia
-
Contact:
- Elena Papamichael, PhD Cand
- Phone Number: 00357 99886346
- Email: papamichael.e1@live.unic.ac.cy
-
Principal Investigator:
- Elena Papamichael, PhD Cand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
For the first interventional phase:
Inclusion Criteria:
1. Male and female over 18 years old 2. Persons with independent gait 3. Normal cognitive ability 5. Greek Native language
Exclusion Criteria:
- Presence of neurological disease
- Presence of uncontrolled diseases of the circulatory system
- History of musculoskeletal surgery in the last 6 months
- Use of a walking aid
- Partial or total blindness
For the second interventional phase:
Inclusion Criteria:
- Male and female over 60 years old
- Persons with independent gait
- Normal cognitive ability
5. Greek Native language
Exclusion Criteria:
- Presence of neurological disease
- Presence of uncontrolled diseases of the circulatory system
- History of musculoskeletal surgery in the last 6 months
- Use of a walking aid
- Partial or total blindness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo group
|
The experimental group MR will use the mixed reality project involving activities in a supermarket.
MR HoloLens2 glasses will be used to conduct the program.
The technological equipment that will be used will allow the provision of visual and auditory stimuli.
The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment.
This program offers coordination activities, posture, cognitive activities and balance exercises.
The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
The group of traditional physiotherapy follows the guidelines of EPDA.
Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks.
The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
|
|
Experimental: Mixed Reality interventional Group
|
The experimental group MR will use the mixed reality project involving activities in a supermarket.
MR HoloLens2 glasses will be used to conduct the program.
The technological equipment that will be used will allow the provision of visual and auditory stimuli.
The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment.
This program offers coordination activities, posture, cognitive activities and balance exercises.
The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
The group of traditional physiotherapy follows the guidelines of EPDA.
Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks.
The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
|
|
Experimental: Traditional Physiotherapy Group
|
The experimental group MR will use the mixed reality project involving activities in a supermarket.
MR HoloLens2 glasses will be used to conduct the program.
The technological equipment that will be used will allow the provision of visual and auditory stimuli.
The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment.
This program offers coordination activities, posture, cognitive activities and balance exercises.
The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
The group of traditional physiotherapy follows the guidelines of EPDA.
Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks.
The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EuroQol 5 Dimension 5 Level
Time Frame: baseline, 4weeks follow up
|
Measurement of quality of life.
Likert scoring style (1-5) where higher scores represent worse state of quality of life
|
baseline, 4weeks follow up
|
|
The Short Form (12) Health Survey
Time Frame: baseline, 4weeks follow up
|
Measurement of quality of life: The scores ranged from 0 to 100, where higher scores representing better quality of life
|
baseline, 4weeks follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intrinsic Motivation Inventory
Time Frame: baseline, 4weeks follow up
|
Measurement of intrinsic motivation: That contains 7 subcategories with average score from 1 to 7. Higher scores indicating better motivation
|
baseline, 4weeks follow up
|
|
Mini Balance Evaluation Systems Test
Time Frame: baseline, 4weeks follow up
|
Measurement of functionality and Balance: The scale's scores ranging from 0 to 28, where higher scores represent better functionality
|
baseline, 4weeks follow up
|
|
Multidirectional Reach Test
Time Frame: baseline, 4weeks follow up
|
Measurement of balance and functionality: Is the only scale that includes cm for the measurement of distance.
Most healthy people present 25cm.
People who present less than 18cm, indicates limitations on functional balance
|
baseline, 4weeks follow up
|
|
Nine-Hole Peg Test
Time Frame: baseline, 4weeks follow up
|
Measurement of fine motor skills and functionality: The test scores are based on the average duration of four trials.
Healthy females present 17.9-19.6
second and males 19-20.6 seconds.
Higher average duration indicates limited fine mobility
|
baseline, 4weeks follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elena Papamichael, PhD Cand, University of Nicosia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ΕΕΒΚ/ΕΠ/2023/07
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Mixed Reality
-
Hospital Moinhos de VentoBrainlab AG; Magic Leap IncCompletedKidney CancerBrazil
-
Universitat Politècnica de CatalunyaCompletedLow Vision | Low Vision Aids | Low Vision Blindness | Low Vision Digital AssistanceSpain
-
Slb PharmaUniversité de Caen Normandie; NeoXpériences, Carpiquet, FranceNot yet recruitingBrain Diseases | Multiple Sclerosis | Cerebral Palsy | Ischemic Stroke | Head Trauma | Neurological Conditions | Parkinson Disease (PD) | Cerebral AnoxiaFrance
-
University of Alabama at BirminghamFrom The Future LLCCompleted
-
Nanjing First Hospital, Nanjing Medical UniversityCompleted
-
Nanjing First Hospital, Nanjing Medical UniversityCompleted
-
Mahidol UniversityEnrolling by invitationMild Cognitive Impairment (MCI) | Executive DysfunctionThailand
-
Shanghai Chest HospitalRecruiting
-
Stanford UniversityCompleted
-
Université de Reims Champagne-ArdenneNot yet recruitingImpact of Mixed Reality Training on Motor Skills in Children With Autistic Spectrum Disorder (RAMAu)Autistic Spectrum Disorder